Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | PNMT | P11086 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL8858 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL1560962 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747797 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747801 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL8859 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL15094242 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL9673275 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13746679 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL910141 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL4781164 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2933 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027043-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | claimed |
| US-20250352466-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA INC (US) | 2025-11-20 | — | — | US | claimed |
| US-12458592-B1 | Extended release amphetamine tablets | TRIS PHARMA, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250320178-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2025-10-16 | — | — | US | claimed |
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | Pharmapotheca A, Inc. | 2025-06-26 | — | — | US | claimed |
| US-20250064747-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA, INC. (US) | 2025-02-27 | — | — | US | claimed |
| US-20250025432-A1 | METHODS FOR IMPROVING DRIVING BEHAVIOR | TRIS PHARMA INC (US) | 2025-01-23 | — | — | US | claimed |
| EP-0987332-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | Kaneka Corporation (JP) | 2000-03-22 | — | — | EP | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
| EP-0110955-B1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIV FLORIDA (US) | 1995-08-23 | — | — | EP | claimed |
| US-5440062-A | One-(substituted)amino-7-(substituted)imino-1,3,5-cycloheptatriene-metal complexes as catalysts | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-08-08 | — | — | US | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| WO-1989010916-A1 | ENANTIOSELECTIVE ADDITION OF HYDROCARBONS TO ALPHA,BETA-UNSATURATED CARBONYL COMPOUNDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-11-16 | — | — | WO | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| US-4479932-A | DIHYDROPYRIDINE PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1984-10-30 | — | — | US | claimed |